27th Feb 2019 14:12
LONDON (Alliance News) - Pharmaceutical firm Indivior PLC on Wednesday said it has launched its schizophrenia treatment Risperidone in the US.
Risperidone, which is sold under the name Perseris, is approved by the US Food & Drug Administration and is an extended-release delivery system.
It is administered under the skin on the abdomen, Indivior said, and releases over one month.
Indivior's Chief Medical Officer commented: "Schizophrenia is a complex disease and part of the complexity is that a patient may not recognize they are ill and therefore not see the need to take medicine.
"Perseris is a once-monthly injection of a commonly prescribed medication known to reduce symptoms of schizophrenia and does not depend on the patient taking additional oral medication. Reducing the symptoms of schizophrenia is very important to help reduce the abnormal behaviours that can lead to the stigma of this disease."
Indivior shares were 0.4% higher on Wednesday at 105.15 pence each.
Related Shares:
Indivior